IP Library Granted Patent US 11,866,474
Granted Patent B2
US 11,866,474 · App. 18/069,797 · Granted Jan 9, 2024

Modulating angiogenesis by proteomimetics of vascular endothelial growth factor

Inventors: Jianfeng Cai (Tampa, FL); Sami Abdulkadir (Tampa, FL)
Assignee: UNIVERSITY OF SOUTH FLORIDA
C07K14/475A61P9/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,866,474
App. No.
18/069,797
Granted
Jan 9, 2024
Kind
B2
Abstract

Provided herein are novel VEGF mimics, pharmaceutical compositions thereof, and methods of their use in increasing or reducing angiogenesis.

Claims (29)

1. A sulfono-γ-AA peptide according to Formula 1 and having the structure:

2. A method of reducing cell migration in a population of cells, the method comprising administering to the cells the sulfono-γ-AA peptide of claim 1 .

3. A method of reducing capillary tube formation in a population of cells, the method comprising administering to the cells the sulfono-γ-AA peptide of claim 1 .

4. A pharmaceutical composition comprising:

the sulfono-γ-AA peptide of claim 1 ; and

a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4 , further comprising at least one of:

a sulfono-γ-AA peptide according to Formula 3 and having the structure:

and

a sulfono-γ-AA peptide according to Formula 2 and having the structure:

6. A method of reducing angiogenesis in a subject in need thereof comprising administering to the subject a therapeutically acceptable amount of the pharmaceutical composition of claim 4 .

7. The method of claim 6 , wherein the subject in need thereof has, or is suspected of having, a cancer or retinopathy.

8. A sulfono-γ-AA peptide according to Formula 3 and having the structure:

9. A method of reducing cell migration in a population of cells, the method comprising administering to the cells the sulfono-γ-AA peptide of claim 8 .

10. A method of reducing capillary tube formation in a population of cells, the method comprising administering to the cells the sulfono-γ-AA peptide of claim 8 .

11. A pharmaceutical composition comprising:

the sulfono-γ-AA peptide of claim 8 ; and

a pharmaceutically acceptable carrier.

12. A method of reducing angiogenesis in a subject in need thereof comprising administering to the subject a therapeutically acceptable amount of the pharmaceutical composition of claim 11 .

13. The method of claim 12 , wherein the subject in need thereof has, or is suspected of having, a cancer or retinopathy.

14. A sulfono-γ-AA peptide according to Formula 2 and having the structure:

15. A method of increasing cell migration in a population of cells, the method comprising administering to the cells the sulfono-γ-AA peptide of claim 14 .

16. A method of increasing capillary tube formation in a population of cells, the method comprising administering to the cells the sulfono-γ-AA peptide of claim 14 .

17. A pharmaceutical composition comprising:

the sulfono-γ-AA peptide of claim 14 ; and

a pharmaceutically acceptable carrier.

18. A method of increasing angiogenesis in a subject in need thereof comprising administering to the subject a therapeutically acceptable amount of the pharmaceutical composition of claim 17 .

19. The method of claim 18 , wherein the subject in need thereof has, or is suspected of having, ischemic heart disease.

20. The method of claim 18 , wherein the subject in need thereof has a wound or damage to an organ.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2023
From: CAI, JIANFENG; ABDULKADIR, SAMI
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 064320/0815 →
CONFIRMATORY LICENSE Recorded Jan 9, 2023
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062321/0831 →
Continuity (2)
Provisional Application 63265835 · Dec 21, 2021
Related Publication 20230220028A1 · Jul 13, 2023